Flerie Invest

AnaCardio is a clinical stage biopharmaceutical company focused on developing innovative drugs for the treatment of heart failure. The company's therapeutics aim to enhance the contractility of the heart muscle through a unique mechanism that utilizes a therapeutic peptide. This approach is designed to avoid common adverse effects associated with traditional treatments, such as tachycardia, arrhythmia, ischemia, or hypotension. By improving cardiac output safely, AnaCardio's drugs have the potential to enhance organ function, elevate quality of life, increase functional capacity, and lower the risks of hospitalization and mortality for patients suffering from heart failure.

Vitara Biomedical is focused on developing a therapeutic platform designed to support premature infants. The company draws inspiration from natural physiological processes to improve neonatal care, aiming to enhance the quality of life for these vulnerable newborns. By addressing the unique challenges faced by premature infants, Vitara Biomedical seeks to reduce mortality rates and associated health complications, ultimately providing a foundation for a healthier future for both infants and their families.

Microbiotica Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing human microbiome-based therapeutics. Founded in 2016, the company operates a platform that identifies gut bacteria associated with specific phenotypes from clinical trial samples. This advanced platform allows researchers to pinpoint gut bacteria with high precision, facilitating the development of live bacterial therapeutics and biomarkers. By enabling the identification of phenotypes prior to testing candidate bacteria in sophisticated human in vitro and in vivo models, Microbiotica aims to advance the understanding and application of microbiome science in therapeutic contexts.

Synerkine Pharma is engaged in the development of innovative fusion proteins aimed at treating inflammatory, neuropathic, and osteoarthritic pain. The company's focus lies in targeting common regulatory mechanisms associated with various forms of chronic pain. Its fusion proteins possess distinctive properties that help normalize pain and inhibit inflammation, thereby offering potential solutions for patients suffering from different pain types. Through its research and development efforts, Synerkine Pharma seeks to provide pharmaceutical products that effectively reduce pain, as demonstrated in multiple pre-clinical models.

Prokarium is a biopharmaceutical company developing microbial immunotherapy and cancer vaccines through a synthetic biology platform. It focuses on immuno-oncology programs designed to evoke durable antitumor responses by re-engineering biological processes to stimulate the immune system. The lead program targets bladder cancer, aiming to transform treatment by orchestrating immune-driven, long-lasting antitumor effects.

Lipum AB is a clinical-stage biopharmaceutical company based in Umeå, Sweden, focused on developing innovative treatments for chronic inflammatory diseases. The company's lead candidate, SOL-116, is a humanized antibody designed to target a previously unexplored molecule in the immune system, offering potential benefits over existing therapies. Lipum's biological treatments aim to alleviate symptoms for patients who do not respond or only respond temporarily to current TNF-alpha inhibitors. The company is particularly dedicated to treating rheumatoid arthritis, a debilitating autoimmune disease, and juvenile idiopathic arthritis, a rare condition affecting children. Lipum also investigates treatments for other chronic inflammatory conditions, including Crohn’s disease, ulcerative colitis, ankylosing spondylitis, and psoriatic arthritis, with the goal of reducing dependency on corticosteroids and immunosuppressants while minimizing adverse effects.

Vitara Biomedical is focused on developing a therapeutic platform designed to support premature infants. The company draws inspiration from natural physiological processes to improve neonatal care, aiming to enhance the quality of life for these vulnerable newborns. By addressing the unique challenges faced by premature infants, Vitara Biomedical seeks to reduce mortality rates and associated health complications, ultimately providing a foundation for a healthier future for both infants and their families.

AnaCardio is a clinical stage biopharmaceutical company focused on developing innovative drugs for the treatment of heart failure. The company's therapeutics aim to enhance the contractility of the heart muscle through a unique mechanism that utilizes a therapeutic peptide. This approach is designed to avoid common adverse effects associated with traditional treatments, such as tachycardia, arrhythmia, ischemia, or hypotension. By improving cardiac output safely, AnaCardio's drugs have the potential to enhance organ function, elevate quality of life, increase functional capacity, and lower the risks of hospitalization and mortality for patients suffering from heart failure.

XNK Therapeutics is a clinical-stage biotechnology company based in Stockholm, Sweden, specializing in immunotherapy for cancer prevention and treatment. The company is focused on developing innovative autologous natural killer (NK) cell-based therapies using its proprietary technology platform. XNK Therapeutics has positioned itself as a leader in the clinical development and manufacture of these therapies, which are designed to effectively target cancers, particularly in scenarios where allogeneic cell products may not be suitable. By harnessing the unique properties of its investigational drug candidates, XNK Therapeutics aims to play a crucial role in advancing cancer treatment strategies.

Founded in 2016, Geneos Therapeutics specializes in developing personalized cancer immunotherapies targeting neoantigens. Its proprietary platform enables the creation of tailored treatments based on individual patients' tumor mutations.

Strike Pharma specializes in personalized cancer treatments using its proprietary Adaptable Drug Affinity Conjugate (ADAC) technology. The company employs an antibody-based technique tailored to each patient's tumor genetic profile, selectively destroying tumor cells while minimizing harm to normal cells and reducing side effects. This approach aims to provide patients with affordable, effective treatment.

Microbiotica Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing human microbiome-based therapeutics. Founded in 2016, the company operates a platform that identifies gut bacteria associated with specific phenotypes from clinical trial samples. This advanced platform allows researchers to pinpoint gut bacteria with high precision, facilitating the development of live bacterial therapeutics and biomarkers. By enabling the identification of phenotypes prior to testing candidate bacteria in sophisticated human in vitro and in vivo models, Microbiotica aims to advance the understanding and application of microbiome science in therapeutic contexts.

Synerkine Pharma is engaged in the development of innovative fusion proteins aimed at treating inflammatory, neuropathic, and osteoarthritic pain. The company's focus lies in targeting common regulatory mechanisms associated with various forms of chronic pain. Its fusion proteins possess distinctive properties that help normalize pain and inhibit inflammation, thereby offering potential solutions for patients suffering from different pain types. Through its research and development efforts, Synerkine Pharma seeks to provide pharmaceutical products that effectively reduce pain, as demonstrated in multiple pre-clinical models.

Founded in 2008, Amarna Therapeutics develops viral vector-based therapies and vaccines using its proprietary SVac platform. The company focuses on genetic disorders, allergies, cancer, and autoimmune diseases. It collaborates with leading research institutions worldwide to create innovative interventions that improve patient outcomes and reduce healthcare costs.

EpiEndo Pharmaceuticals is a clinical-stage biopharmaceutical company focused on inflammatory disorders by strengthening epithelial barrier integrity, a key factor in the progression of diseases affecting the skin, lungs, intestinal tract, and genital tract. It develops proprietary, orally available macrolide drug candidates with potential as first-in-class, disease-modifying therapies for chronic respiratory diseases and other significant unmet medical needs. Its lead candidate, EP395, aims to be the first oral, non-antibiotic macrolide that reinforces barrier function and provides anti-inflammatory effects for COPD and related inflammatory airway conditions.

KAHR medical is a biopharmaceutical company developing fusion protein drugs for cancer and autoimmune disease treatment. Founded in 2005, it specializes in immuno-oncology, focusing on T-cell mediated tumor destruction and targeting CD47 tumors.

Prokarium is a biopharmaceutical company developing microbial immunotherapy and cancer vaccines through a synthetic biology platform. It focuses on immuno-oncology programs designed to evoke durable antitumor responses by re-engineering biological processes to stimulate the immune system. The lead program targets bladder cancer, aiming to transform treatment by orchestrating immune-driven, long-lasting antitumor effects.

KAHR medical is a biopharmaceutical company developing fusion protein drugs for cancer and autoimmune disease treatment. Founded in 2005, it specializes in immuno-oncology, focusing on T-cell mediated tumor destruction and targeting CD47 tumors.

Founded in 2008, Amarna Therapeutics develops viral vector-based therapies and vaccines using its proprietary SVac platform. The company focuses on genetic disorders, allergies, cancer, and autoimmune diseases. It collaborates with leading research institutions worldwide to create innovative interventions that improve patient outcomes and reduce healthcare costs.

Founded in Sweden in 2013, Empros Pharma develops innovative pharmaceutical treatments focused on addressing overweight and obesity. Their flagship product, EMP16, is an oral drug designed to delay digestion and regulate food intake.

Prokarium is a biopharmaceutical company developing microbial immunotherapy and cancer vaccines through a synthetic biology platform. It focuses on immuno-oncology programs designed to evoke durable antitumor responses by re-engineering biological processes to stimulate the immune system. The lead program targets bladder cancer, aiming to transform treatment by orchestrating immune-driven, long-lasting antitumor effects.

OxThera AB is a biopharmaceutical company focused on developing innovative therapies for the treatment of primary and secondary hyperoxaluria, a condition that can lead to kidney damage. Founded in 2005 and headquartered in Stockholm, Sweden, with an additional facility in Knoxville, Tennessee, OxThera specializes in products that utilize bacteria and enzymes to manage oxalate levels in the body. Its leading products include Oxabact, an oral formulation of live bacteria designed to enhance the elimination of oxalate produced endogenously, and Oxazyme, a non-systemic oral drug made from recombinant oxalate decarboxylase aimed at treating dietary hyperoxaluria and preventing kidney stones. Oxabact has received Orphan Drug designations in both Europe and the United States, underscoring its potential in addressing unmet medical needs in this therapeutic area. The company holds worldwide patents for its unique compositions and treatment methods targeting hyperoxaluria.

KAHR medical is a biopharmaceutical company developing fusion protein drugs for cancer and autoimmune disease treatment. Founded in 2005, it specializes in immuno-oncology, focusing on T-cell mediated tumor destruction and targeting CD47 tumors.

Founded in Sweden in 2013, Empros Pharma develops innovative pharmaceutical treatments focused on addressing overweight and obesity. Their flagship product, EMP16, is an oral drug designed to delay digestion and regulate food intake.

KAHR medical is a biopharmaceutical company developing fusion protein drugs for cancer and autoimmune disease treatment. Founded in 2005, it specializes in immuno-oncology, focusing on T-cell mediated tumor destruction and targeting CD47 tumors.

Prokarium is a biopharmaceutical company developing microbial immunotherapy and cancer vaccines through a synthetic biology platform. It focuses on immuno-oncology programs designed to evoke durable antitumor responses by re-engineering biological processes to stimulate the immune system. The lead program targets bladder cancer, aiming to transform treatment by orchestrating immune-driven, long-lasting antitumor effects.